The Clinical Significance Of CD105 Expression In Endometrial Carcinoma

Objective: Tumor's growth and invasion depend onangiogenesis. The neogenetic vessels supply nutrition andoxygen to tumor and provid foundation for tissue proliferation.So the microvascular counts in tumor is closely correlated withthe tumorous biological behaviour. Many studies haveconfirmed that microvessel density (MVD) is concerned withprognosis of the patients sufferred with cancer. In the studies ofendometrial cancer, some studies consider that MVD can be theindependent prognosis factor , but other results contrary to that.The major reason of the difference is possibly using differentendothelial cell markers and different count methods. CD105 isa kind of glycoproteins idio-expressed in the neogenetic vesselsand principally marks the endothelial cells with proliferatingactivity. Some studies have documented that MVD labelled withCD105 is superior to other tumor markers and can reflecttumor's proliferating status and prognosis. So our study hasinvestigated the relationship between CD105 and theendometrial tumor's generation, development and prognosis incomparing with CD34, a pan-endothelial cell marker, anddetecting the important vessel endothelium growth factor(VEGF) and Ki-67 which can reflect the tumor's proliferatingstatus. We can provide the theoretical evidence for the currentCD105 targeted therapy by this study.Methods: 25 cases of endometrial cancer and 10 cases ofatypical hyperplasia and 8 cases of normal endometrium werecollected from patients who had treated in years between2002-2004 in our hospital. All endometrial cancer wereadenocarcinoma. According to the standard of FIGOoperation-pathology stage and pathological grade the cancersamples were divided: stageⅠ(6 cases),stageⅡ(10 cases),stage Ⅲ(9 cases); well-differentiated(G1)(15 cases),moderate-differentiated(G2)(4 cases), poor -differentiated(G3)(6cases); According to the depth of infiltrating muscular layer: <1/2 muscular layer(11 cases),≥1/2 muscular layer(14 cases);The regional lymph node had been infiltrated in 12 cases andnot in 13 cases. The expression of CD105,CD34 ,Ki-67, VEGFwas detected by immunohistochemistry SP method. The specificprocedure was carried out according to the description. Boilingmethod was used in antigen restore and DAB was used incoloration. The foregone positive section served as the positivecontrol and phosphate buffer replacing the primary antibodyserved as the negative control. SPSS11.0 statistic software wasused in statistics.Results: CD105 principally expressed in the small vesselsat the tumor's margin and the large vessels were not obviouslystained. All samples expressed CD105. However, CD34expressed strongly in the small vessels and in the large vesselsat margin or interior of the tumor. CD105-MVD value of thecontrol group, the atypical hyperplasia group and theendometrial cancer group was 12.667±2.575, 28.467±5.242,28.680±5.808 by turns , which showed a gradual heighteningtendency. CD105-MVD of The endometrial cancer group andatypical hyperplasia group was significantly higher than that ofthe control group. CD105-MVD of the endometrial cancergroup and atypical hyperplasia group was approximate. Thedifference was not statistically significant. CD34-MVD valuewas obviously higher than CD105-MVD. The three groupsvalue were 19.125±4.185, 32.167±6.125, 36.240±6.577 byturns, and the difference is statistically significant. Therelationship between CD105-MVD and the clinicopathologicfactors of endometrial cancer: CD105-MVD was not correlatedwith the menopause and the grade, but significantly correclatedwith the FIGO stage , depth of infiltrating muscular layer andthe focal lymph node infiltrated. The higher stage , the higherCD105-MVD. CD105-MVD of >1/2 depth of infiltratingmuscular layer was significantly higher than that of ≤1/2 depth.CD105-MVD of region lymph node infiltrated was significantlyhigher than that of no region lymph node infiltrated. However,CD34-MVD was only correlated with the FIGO stage and notcorrelated with the other clinicopathologic factors. Correlationanalysis indicated that CD105-MVD was significantlycorreclated with CD34-MVD ( r=0.495 , P=0.001 ) .Therelationship between CD105-MVD and Ki-67: The PI valuegradually heighten in the control group, the atypical hyperplasiagroup and the endometrial cancer group. PI of the atypicalhyperplasia group was significantly higher than that of thecontrol group and the endometrial cancer group wassignificantly higher than that of the atypical hyperplasia groupand the control group. PI of endometrial cancer was onlycorrelated with the FIGO grade but not correlated with the otherclinicopathologic factors. CD105-MVD was significantlycorreclated with Ki-67 expression(r=0.641,P<0.01=. Therelationship between CD105-MVD and VEGF: The VEGFpositive percentage of the control group, the atypicalhyperplasia group and the endometrial cancer group was 25%(2/8),30%(3/10),80%(20/25) by turns. The differencebetween the endometrial cancer group and the other two groupswas statistically significance. The difference between theatypical hyperplasia group and the control group was notstatistically significance. VEGF was not correlated with theclinicopathologic factors. Correlation analysis indicated thatCD105-MVD was significantly correclated with VEGF(r=0.389,P=0.01).Conclusion: 1.Atypical hyperplasia and endometrialcancer both have strong capability of angiogenesis.CD105-MVD value can be used to predict the canceroustendency. 2.CD105-MVD is positive correlate with theexpression of Ki-67, and it can reflect the tissue proliferatingstatus of endometrial cancer. 3.CD105-MVD is better than...